Company intelligence / Profile preview

Fluent BioSciences

Watertown, Massachusetts, United Statesfluentbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Fluent BioSciences developed and commercialized the PIPseq™ single-cell RNA sequencing platform. This technology eliminates the need for complex microfluidic devices or expensive instrumentation by using pre-templated instant partitions to enable scalable, cost-effective single-cell transcriptomics. The company’s solutions are designed to make high-throughput single-cell analysis accessible to more labs by reducing workflow complexity and cost. In July 2024, Fluent was acquired by Illumina to expand its multiomics capabilities.

Therapeutic areas: Other
Modalities: Single-cell RNA sequencing (scRNA-seq)single-cell analysis kits and reagents
Industry: Molecular Diagnostics

Partnerships

Now part of Illumina’s ecosystem; previously supported by investors including Civilization

Beyond the preview

Go deeper on Fluent BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fluent BioSciences.

Explore the full profile